The World Health Organization estimates that approximately 350 million people worldwide are long-term carriers of HBV, including 1,200,000 Americans. The American Liver Foundation estimates that there are 140,000 new HBV infections in the U.S. each year and that one of every 20 people in the U.S. will be infected with HBV in their lifetime. Up to 40 percent of people with acute HBV infection show no symptoms. Many people chronically infected with HBV will progress to liver cirrhosis and liver failure, from which they will eventually die. People with chronic HBV infection have a 100 times greater chance of developing hepatocellular carcinoma than those not infected.
Hepatocellular carcinoma is one of the most prevalent malignant diseases in the world.
Zadaxin is approved for sale in 24 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. In Europe, a phase 3 Zadaxin program will be undertaken which would complement the Company's U.S. clinical program. Zadaxin is also in clinical trials in Japan and Australia. SciClone Pharmaceuticals . Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.